Ann: FDA Grants Rare Pediatric Disease Designation for Revascor, page-226

Well maybe you should read the whole article before you get too excited?

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10775099/

Cardiac MRI revealed no significant difference between the groups in changes in LVEDV (P = .87) or LVESV (P = .79) from baseline to 12 months. The median LVEDV at 12 months was 40.4 mL/m² (IQR, 29.2-73.9 mL/m²) in the MPC group and 47.6 mL/m² (IQR, 37.7-52.4 mL/m²) in the control group. As demonstrated in the 3D echocardiography data, there was no significant difference between the groups in changes in LV mass (P = .71) or LV ejection fraction (P > .99). These imaging data are presented in Table 3 and Figure 5. The 2D echocardiography data showed similar trends as the 3D measurements (Table E1).